Li-Fraumeni Syndrome Clinical Trials

9 recruiting

Li-Fraumeni Syndrome Trials at a Glance

9 actively recruiting trials for li-fraumeni syndrome are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 1 trial, with the heaviest enrollment activity in Bethesda, Bologna, and Boston. Lead sponsors running li-fraumeni syndrome studies include Dana-Farber Cancer Institute, Istituto Ortopedico Rizzoli, and Abramson Cancer Center at Penn Medicine.

Browse li-fraumeni syndrome trials by phase

Treatments under study

About Li-Fraumeni Syndrome Clinical Trials

Looking for clinical trials for Li-Fraumeni Syndrome? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Li-Fraumeni Syndrome trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Li-Fraumeni Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

ObesityCardiomyopathyLi-Fraumeni Syndrome+3 more
National Heart, Lung, and Blood Institute (NHLBI)5,000 enrolled3 locationsNCT01143454
Recruiting

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NeoplasmsLi-Fraumeni SyndromeTp53 Mutations
National Cancer Institute (NCI)5,000 enrolled2 locationsNCT01443468
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Hereditary Breast and Ovarian CancerHodgkin LymphomaAdrenocortical Carcinoma+30 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting

Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling

Li-Fraumeni Syndrome
M.D. Anderson Cancer Center500 enrolled1 locationNCT05126810
Recruiting

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

Hereditary Cancer SyndromeLi-Fraumeni SyndromeTP53 Gene Mutation+2 more
Dana-Farber Cancer Institute1,500 enrolled3 locationsNCT04541654
Recruiting

Registry of Li Fraumeni and Li Fraumeni Like Syndromes

Li-Fraumeni SyndromeLi-Fraumeni-Like Syndrome
Istituto Ortopedico Rizzoli200 enrolled2 locationsNCT04982744
Recruiting

Li-Fraumeni Syndrome/TP53 Biobank

Li-Fraumeni SyndromeLi-Fraumeni-Like Syndrome
Abramson Cancer Center at Penn Medicine300 enrolled2 locationsNCT04367246
Recruiting

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

Neuroendocrine NeoplasmParagangliomaPheochromocytoma+23 more
Universidad Nacional Autonoma de Mexico750 enrolled3 locationsNCT06523582
Recruiting
Phase 2

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Li-Fraumeni SyndromePediatric Cancerp53 Mutations
Yang Li50 enrolled1 locationNCT06088030